Pouch Market Review - VELO revenue up 220% while On! shipments fall in Q2
After reviewing the H1 2026 numbers, it seems the gap between brands is a lot wider than expected.
BAT: VELO revenue is up 220%, and volume is up 188% YoY. With VELO Max coming later this year, it's looking good for BAT.
PMI: record quarter on paper, net revenues up 10.4% and past $11B for the first time. ZYN shipments grew by 1.8%, and ZYN Ultra launched this summer and was noted as the first phase of their portfolio expansion - so can we expect more to come?.
Altria: the weak one? Q2 on! shipments down 4.2% YoY, and they missed profit estimates. They're responding with more on! Plus flavors, strengths up to 12mg, and wider distribution. So we will see how that unfolds going into 2027.
Turning Point Brands (ALP, FRE): modern oral revenue up 149%, gross profit up 40.6%, and ALP is launching in the UK and EU. The stock price isn't reflecting the gross revenue though and is still down 20%+.
Read more about it on our blog: https://prilla.com/us/blog/nicotine-pouch-market-report
ZYN growing 1.8% while VELO flies is what stands out to me. Is ZYN hitting saturation, or are people actually preferring VELO Plus? And with VELO Max on the horizon, will this make things worse for ZYN and its new Ultra line? It'll be interesting to see where things end up this time next year!